M. Michael

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry et al. · Annals of Oncology · 2009 · 532 citations

Oncology, First-line Bevacizumab, Gastrointestinal Oncology +10

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

Grace Kong, Matthew Thompson, Marnie Collins et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2014 · 89 citations · Full text

Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial

Scott Berry, David Cunningham, M. Michael et al. · Journal of Clinical Oncology · 2006 · 42 citations

Cancer Management, Preliminary Safety, Multimodality +22

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer

Benjamin Solomon, David Ball, Gary Richardson et al. · Lung Cancer · 2003 · 19 citations

Weekly Cisplatin, Concurrent Twice-weekly Paclitaxel, Phase I/ii Study +8

Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial

Albrecht Kretzschmar, Eric Van Cutsem, M. Michael et al. · Journal of Clinical Oncology · 2007 · 19 citations

Disease Progression, Cancer Management, Multimodality +16